Statin use and the risk of liver cancer: A population-based case-control study

American Journal of Gastroenterology

Volumn 106, Issue 5, 2011, Pages 894-898

  Chiu, Hui Fen ^a   Ho, Shu Chen ^b   Chen, Chih Cheng ^c   Yang, Chun Yuh ^b  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^c CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ADULT; AGE; AGED; ARTICLE; CANCER RISK; CONTROLLED STUDY; DRUG USE; FEMALE; HUMAN; INFORMATION PROCESSING; LIVER CANCER; MAJOR CLINICAL STUDY; MALE; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; SEX; STATISTICAL ANALYSIS; TAIWAN;

AGED; CASE-CONTROL STUDIES; CONFOUNDING FACTORS (EPIDEMIOLOGY); FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIVER NEOPLASMS; MALE; MIDDLE AGED;

EID: 79955595053     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2010.475     Document Type: Article

References (45)

1. Wong WW, Dimitroulakos J, Minden MD et al. HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apotosis. Leukemia 2002; 16: 508-519. (Pubitemid 34460459)
2. Hebert PR, Gaziano JM, Chan KS et al. Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. JAMA 1997; 278: 313-321. (Pubitemid 27339660)
3. Baigent C, Keech A, Kearney PM et al. Efficacy and safety of cholesterollowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomized trials of statins. Lancet 2005; 366: 1267-1278.
4. Newman TB, Hulley SB. Carcinogenicity of lipid-lowering drugs. JAMA 1996; 275: 55-60. (Pubitemid 26004257)
5. Keyomarsi K, Sandoval L, Band V et al. Synchronization of tumor and normal cells from G1 to multiple cell cycles by lovastatin. Cancer Res 1991; 51: 3602-3609.
6. Dimitroulakos J, Marhin WH, Tokunaga J et al. Microarray and biochemical analysis of lovastatin-induced apotosis of squamous cell carcinoma. Neoplasia 2002; 4: 337-346. (Pubitemid 34755844)
7. Weis M, Heeschen C, Glassford AJ et al. Statins have biphasic effects on angiogenesis. Circulation 2002; 105: 739-745. (Pubitemid 34157379)
8. Park HJ, Hong D, Iruela-Arispe L et al. 3-hydroxy-3-methylglutaryl- coenzyme A reductase inhibitors interfere with angiogenesis by inhibiting the geranylgeranylation of RhoA. Circ Res 2002; 91: 143-150. (Pubitemid 34827225)
9. Alonso DF, Farina HG, Skilton G et al. Reduction of mouse mammary tumor formation and metastasis by lovastatin, an inhibitor of the mevalonate pathway of cholesterol synthesis. Breast Cancer Res Treat 1998; 50: 83-93. (Pubitemid 28438864)
10. Kusama T, Mukai M, Iwasaki T et al. 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors reduce human pancreatic cancer cell invasion and metastasis. Gastroenterology 2002; 122: 308-317. (Pubitemid 34116983)
11. Kaye JA, Jick H. Statin use and cancer risk in the General Practice Research Database. Br J Cancer 2004; 90: 635-7. (Pubitemid 38297203)
12. Dale KM, Coleman CI, Henyan NN et al. Statins and cancer risk: a metaanalysis. JAMA 2006; 295: 74-80.
13. Coogan PF, Rosenberg L, Strom BL. Statin use and the risk of 10 cancers. Epidemiology 2007; 18: 213-9.
14. Browning DR, Martin RM. Statins and risk of cancer: a systematic review and metaanalysis. Int J Cancer 2006; 120: 833-843.
15. Bonovas S, Filioussi K, Tsavaris N et al. Statins and cancer risk: a literature-based meta-analysis and meta-regression analysis of 35 randomized controlled trials. J Clin Oncol 2006; 24: 4808-4817. (Pubitemid 46655612)
16. Setoguchi S, Glynn RJ, Avorn J et al. Statins and the risk of lung, breast, and colorectal cancer in the elderly. Circulation 2007; 115: 27-33. (Pubitemid 46058608)
17. Kuoppala J, Lamminpaa A, Pukkala E. Statins and cancer: a systematic review and meta-analysis. Eur J Cancer 2008; 44: 2122-2132.
18. Haukka J, Sankila R, Klaukka T et al. Incidence of cancer and statin usagerecord linkage study. Int J Cancer 2010; 126: 279-284.
19. Blais L, Desgagne A, LeLorier J. 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors and the risk of cancer: a nested case-control study. Arch Intern Med 2000; 160: 2363-2368.
20. Boudreau DM, Gardner JS, Malone KE et al. The association between 3-hydroxy-3-methylglutaryl-coenzyme A inhibitor use and breast carcinoma risk among postmenopausal women. Cancer 2004; 100: 2308-2316. (Pubitemid 38657877)
21. Cauley JA, Zmuda JM, Lui LY et al. Lipid-lowering drug use and breast cancer in older women: a prospective study. J Women Health 2003; 12: 749-756. (Pubitemid 37361917)
22. Graaf MR, Beiderbeck AB, Egberts AC et al. The risk of cancer in users of statins. J Clin Oncol 2004; 22: 2388-2394. (Pubitemid 41115396)
23. Poynter JN, Gruber SB, Higgins PD et al. Statins and the risk of colorectal cancer. N Engl J Med 2005; 352: 2184-2192. (Pubitemid 40727085)
24. Shannon J, Tewoderos S, Garzotto M et al. Statins and prostate cancer risk: a case-control study. Am J Epidemiol 2005; 162: 318-325. (Pubitemid 41389713)
25. Khurana V, Bejjanki HR, Caldito G et al. Statins reduce the risk of lung cancer: a large case-control study of US veterans. Chest 2007; 131: 1282-1288. (Pubitemid 46762329)
26. Khurana V, Sheth A, Caldito G et al. Statins reduce the risk of pancreatic cancer in humans: a case-control study of half a million veterans. Pancreas 2007; 34: 260-5. (Pubitemid 46294804)
27. Friis S, Poulsen AH, Johnsen SP et al. Cancer risk among statin users: a population-based cohort study. Int J Cancer 2005; 114: 643-7. (Pubitemid 40349625)
28. Tobert JA. Efficacy and long-term adverse effect pattern of lovastatin. Am J Cardiol 1988; 62: 28J-34J. (Pubitemid 18263853)
29. Kawata S, Yamasaki E, Nagase T et al. Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial. Br J Cancer 2001; 84: 886-891. (Pubitemid 32385829)
30. El-Serag HB, Johnson ML, Hachem C et al. Statins are associated with a reduced risk of hepatocellular carcinoma in a large cohort of patients with diabetes. Gastroenterology 2009; 136: 1601-1608.
31. Chiang CW, Chen CY, Chiu HF et al. Trends in the use of antihypertensive drugs by outpatients with diabetes in Taiwan, 1997-2003. Pharmacoepidemiol Drug Saf 2007; 16: 412-421.
32. Kuo HW, Tsai SS, Tiao MM et al. Epidemiologic features of CKD in Taiwan. Am J Kidney Dis 2007; 49: 46-55.
33. Tiao MM, Tsai SS, Kuo HW et al. Epidemiological features of biliary atresia in Taiwan, a national study 1996-2003. J Gastroenterol Hepatol 2008; 23: 62-6.
34. Coogan PF, Rosenberg L, Palmer JR et al. Statin use and the risk of breast and prostate cancer. Epidemiology 2002; 13: 262-7. (Pubitemid 34415845)
35. Meier CR, Scheinger RG, Kraenzlin ME et al. HMG-CoA reductase inhibitors and the risk of fractures. JAMA 2000; 283: 3205-3210. (Pubitemid 30422037)
36. Jadhav SB, Jain GK. Statins and osteoporosis: new role for old drugs. J Pharm Pharmacol 2006; 58: 3-18. (Pubitemid 43041991)
37. Rejnmark L, Plsen ML, Johnsen SP et al. Hip fracture risk in statin users-a population-based Danish case-control study. Osteoporos Int 2004; 15: 452-8. (Pubitemid 38843173)
38. Wang PS, Solomon DH, Mogun H et al. HMG-CoA reductase inhibitors and the risk of fractures. JAMA 2000; 283: 3211-3216. (Pubitemid 30422038)
39. WHO Collaborating Center for Drugs Statistics Methodology. ATC Index with DDDs 2003. WHO: Oslo, 2003.
40. Danesh FR, Sadeghi MM, Amro N et al. 3-hydroxy-3-methylglutarylcoenzyme A reductase inhibitors prevent high glucose-induced proliferation of mesangial cells via modulation of Rho GTPase/p21 signaling pathway: implications for diabetic nephropathy. Proc Natl Acad Sci USA 2002; 99: 8301-8305. (Pubitemid 34651047)
41. Blanco-Colio LM, Villa A, Ortego M et al. 3-Hydroxy-3- methylglutarylcoenzyme A reductase inhibitors, atorvastatin and simvastatin, induce apotosis of vascular smooth muscle cells by downregulation of Bcl-2 expression and Rho A prenylation. Atherosclerosis 2002; 161: 17-26. (Pubitemid 34214817)
42. Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methylglutaryl- coenzyme A reductase inhibitors. Arterioscler Th romb Vasc Biol 2001; 21: 1712-1719. (Pubitemid 34219772)
43. Shibata MA, avanaugh C, Shibata E et al. Comparative effects of lovastatin on mammary and prostate oncogenesis in transgenic mouse models. Carcinogenesis 2003; 24: 453-9. (Pubitemid 36432640)
44. Rao S, Porter DC, Chen X et al. Lovastatin-mediated G1 arrest is through inhibition of the proteasome, independent of hydroxymethyl glutaryl-CoA reductase. Proc Natl Acad Sci USA 1999; 96: 7797-802. (Pubitemid 29328361)
45. Ye J, Wang C, Sumpter R et al. Disruption of hepatitis C virus RNA replication through inhibition of host protein geranylgeranylation. Proc Natl Acad Sci USA 2003; 100: 15865-70. (Pubitemid 38021081)